gene therapy

Over 50 drugmakers advance 55+ hemophilia treatments as Novo Nordisk and competitors pursue gene therapies and next-gen factors.

Plasmid DNA manufacturing market projected to reach $10.8B by 2034 from $2.4B in 2025 on strong gene therapy demand growth.

Krystal Biotech will present gene therapy data across three major conferences in May-June 2026, highlighting programs targeting ciliary dyskinesia, cystic fibrosis, and immunotherapy.

CRISPR Therapeutics leverages FDA-approved gene editing to target a $223B autoimmune disease market, positioning itself as the post-GLP-1 growth opportunity in biotech.

IgA Nephropathy market projects 18.6% CAGR through 2036 from $1.5B base, driven by novel immunotherapies and recent FDA approvals reshaping kidney disease treatment.

Taysha Gene Therapies will report Q1 2026 financial results and discuss TSHA-102 Rett syndrome program progress on May 6, 2026.

AAV vector manufacturing market to surge from $874M (2025) to $5.2B (2034) as gene therapy breakthroughs drive demand for specialized production infrastructure.

Eli Lilly's oncology and immunology portfolios rival its blockbuster weight-loss drugs, positioning the company better than Novo Nordisk for long-term growth.

Regeneron agrees with Trump Administration to lower drug prices via Medicaid benchmarking and free gene therapy access, receiving three years of tariff relief and regulatory certainty.

FDA approves $REGN's Otarmeni, first dual AAV gene therapy for genetic hearing loss, in record 61 days under priority voucher program. 80% of patients showed improved hearing.

Regeneron offers gene therapy Otarmeni free and Praluent at lower pricing in exchange for tariff relief and exemption from future pricing mandates.

Vertex's cystic fibrosis market dominance faces gene therapy competition post-patent expiration, but patent protection extends through late 2030s while diversification efforts hedge risk.

MeiraGTx acquires J&J's bota-vec gene therapy for rare blindness in $25M deal, targeting 2027 launch with promising Phase 3 clinical data.

Pomerantz Law Firm files class action suit against $RGNX after FDA clinical hold on gene therapy candidates triggers 17.9% stock collapse. Investor deadline: April 14, 2026.

REGENXBIO faces class action lawsuit after FDA halted RGX-111 gene therapy trial due to CNS tumor, triggering 18% stock decline.

CRISPR Therapeutics holds $2B cash reserves funding gene-therapy expansion, while Casgevy sales accelerate to $116M in 2025.

Alpha thalassemia market poised for significant expansion driven by rising prevalence, diagnostic advances, and pipeline therapies from $AGIOS and $NVO through 2036.

REGENXBIO ($RGNX) investors have until April 14, 2026 to join securities class action over allegedly misleading RGX-111 trial statements.

Hagens Berman investigates $QURE for allegedly misrepresenting FDA interactions on AMT-130 gene therapy. Stock crashed 49% November 3 after FDA disagreement revealed.

Longevity biotech sector surges toward $29.7B market by 2034 as companies advance cell therapies for age-related diseases, with multiple clinical programs showing promising results.